
Simulations Plus (SLP) Stock Forecast & Price Target
Simulations Plus (SLP) Analyst Ratings
Bulls say
Simulations Plus Inc. reported total revenue of $20.4 million for the third fiscal quarter (F3Q), which met consensus expectations and exceeded its guidance range, indicating stable financial performance. The company anticipates a potential acceleration in organic revenue growth towards high-single digits in FY26, driven by the recent Proficiency acquisition, which may mitigate the impact of customer cancellations. With a robust revenue mix of approximately 55-60% from software and 40-45% from services, the company is well-positioned within the pharmaceutical research and consulting sectors.
Bears say
Simulations Plus Inc. faces significant challenges in the biopharma end market due to its concentrated customer base and exposure to the biotech sector, leading to expectations of continued weak customer demand in the near-to-middle term. In its most recent financial results, the company reported third-quarter software revenue of $12.6 million, which fell short of the $13.6 million consensus estimate, despite service revenue exceeding expectations. Additionally, elevated SG&A expenses of $8.8 million, which were above the consensus of $7.8 million, further complicate the financial outlook amid a landscape lacking signs of recovery in biotech markets.
This aggregate rating is based on analysts' research of Simulations Plus and is not a guaranteed prediction by Public.com or investment advice.
Simulations Plus (SLP) Analyst Forecast & Price Prediction
Start investing in Simulations Plus (SLP)
Order type
Buy in
Order amount
Est. shares
0 shares